Loading...

Molecular Partners

DB:6ML
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6ML
DB
CHF391M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
6ML Share Price and Events
7 Day Returns
-3.3%
DB:6ML
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-26.9%
DB:6ML
-10.2%
DE Biotechs
-6%
DE Market
6ML Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Molecular Partners (6ML) -3.3% 8% 10.8% -26.9% -34.4% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 6ML underperformed the Biotechs industry which returned -10.2% over the past year.
  • 6ML underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
6ML
Industry
5yr Volatility vs Market

6ML Value

 Is Molecular Partners undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Molecular Partners. This is due to cash flow or dividend data being unavailable. The share price is €15.98.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Molecular Partners's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Molecular Partners's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6ML PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CHF CHF-1.75
SWX:MOLN Share Price ** SWX (2019-04-18) in CHF CHF18.4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Molecular Partners.

DB:6ML PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:MOLN Share Price ÷ EPS (both in CHF)

= 18.4 ÷ -1.75

-10.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Molecular Partners is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Molecular Partners is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Molecular Partners's expected growth come at a high price?
Raw Data
DB:6ML PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
41.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Molecular Partners, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Molecular Partners's assets?
Raw Data
DB:6ML PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CHF CHF4.32
SWX:MOLN Share Price * SWX (2019-04-18) in CHF CHF18.4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:6ML PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:MOLN Share Price ÷ Book Value per Share (both in CHF)

= 18.4 ÷ 4.32

4.26x

* Primary Listing of Molecular Partners.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Molecular Partners is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Molecular Partners's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Molecular Partners has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6ML Future Performance

 How is Molecular Partners expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Molecular Partners expected to grow at an attractive rate?
  • Molecular Partners's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Molecular Partners's earnings growth is expected to exceed the Germany market average.
  • Molecular Partners's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6ML Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6ML Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 41.3%
DB:6ML Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 26%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6ML Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6ML Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 108 27 61 2
2022-12-31 71 -16 -2 2
2021-12-31 52 -9 -12 3
2020-12-31 82 32 57 3
2019-12-31 29 -32 -43 2
DB:6ML Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2018-12-31 10 -42 -37
2018-09-30 17 -41 -27
2018-06-30 23 -39 -18
2018-03-31 22 -24
2017-12-31 20 -40 -25
2017-09-30 17 -26
2017-06-30 16 -38 -28
2017-03-31 19 -22
2016-12-31 23 -35 -19
2016-09-30 27 -13
2016-06-30 31 18 -3
2016-03-31 30 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Molecular Partners's earnings are expected to grow significantly at over 20% yearly.
  • Molecular Partners's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6ML Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Molecular Partners Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6ML Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.35 2.35 2.35 1.00
2022-12-31 0.80 0.80 0.80 1.00
2021-12-31 -0.52 -0.11 -1.06 3.00
2020-12-31 0.97 2.31 -1.10 4.00
2019-12-31 -1.91 -1.70 -2.25 4.00
DB:6ML Past Financials Data
Date (Data in CHF Millions) EPS *
2018-12-31 -1.75
2018-09-30 -1.30
2018-06-30 -0.84
2018-03-31 -1.13
2017-12-31 -1.22
2017-09-30 -1.26
2017-06-30 -1.36
2017-03-31 -1.07
2016-12-31 -0.91
2016-09-30 -0.65
2016-06-30 -0.14
2016-03-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Molecular Partners will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Molecular Partners's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Molecular Partners has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6ML Past Performance

  How has Molecular Partners performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Molecular Partners's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Molecular Partners does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Molecular Partners's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Molecular Partners's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Molecular Partners's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Molecular Partners Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6ML Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 10.36 -37.04 9.56
2018-09-30 16.90 -27.40 9.28
2018-06-30 23.44 -17.77 9.00
2018-03-31 21.64 -23.69 8.81
2017-12-31 20.02 -25.43 8.41
2017-09-30 16.85 -26.22 7.95
2017-06-30 15.51 -28.26 7.23
2017-03-31 19.34 -22.01 7.64
2016-12-31 23.04 -18.61 7.34
2016-09-30 27.22 -13.45 21.95
2016-06-30 31.41 -2.83 -0.75
2016-03-31 30.12 -1.95 21.45
2015-12-31 29.12 -0.15 6.32
2015-09-30 27.83 -6.38 19.68
2015-06-30 24.64 -10.85 20.54
2015-03-31 25.81 -5.44 15.21
2014-12-31 26.63 -2.28 17.68
2013-12-31 32.42 7.14 14.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Molecular Partners has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Molecular Partners has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Molecular Partners improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Molecular Partners's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Molecular Partners has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6ML Health

 How is Molecular Partners's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Molecular Partners's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Molecular Partners is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Molecular Partners's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Molecular Partners's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Molecular Partners has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Molecular Partners Company Filings, last reported 3 months ago.

DB:6ML Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 91.70 0.00 98.96
2018-09-30 91.70 0.00 98.96
2018-06-30 116.34 0.00 122.36
2018-03-31 116.34 0.00 122.36
2017-12-31 116.73 0.00 141.06
2017-09-30 116.73 0.00 141.06
2017-06-30 118.29 0.00 156.86
2017-03-31 135.80 0.00 180.23
2016-12-31 135.80 0.00 180.23
2016-09-30 141.43 0.00 196.35
2016-06-30 141.43 0.00 196.35
2016-03-31 151.79 0.00 215.39
2015-12-31 151.80 0.00 215.39
2015-09-30
2015-06-30 142.97 0.00 175.63
2015-03-31 148.48 0.00 188.38
2014-12-31 148.48 0.00 188.38
2013-12-31 48.32 0.00 96.13
  • Molecular Partners has no debt.
  • Molecular Partners has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Molecular Partners has sufficient cash runway for 2.3 years based on current free cash flow.
  • Molecular Partners has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 61.6% each year.
X
Financial health checks
We assess Molecular Partners's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Molecular Partners has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6ML Dividends

 What is Molecular Partners's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Molecular Partners dividends. Estimated to be 0% next year.
If you bought €2,000 of Molecular Partners shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Molecular Partners's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Molecular Partners's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6ML Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6ML Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Molecular Partners has not reported any payouts.
  • Unable to verify if Molecular Partners's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Molecular Partners's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Molecular Partners has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Molecular Partners's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Molecular Partners's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Molecular Partners afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Molecular Partners has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6ML Management

 What is the CEO of Molecular Partners's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Patrick Amstutz
COMPENSATION CHF909,000
AGE 43
TENURE AS CEO 2.4 years
CEO Bio

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting Chief Executive Officer of Molecular Partners AG since November 7, 2016. Dr. Amstutz served as the Chief Operating Officer of Molecular Partners AG. since 2014 until November 7, 2016. Dr. Amstutz served as Chief Business Officer of Molecular Partners AG from 2006 to 2014. He has been a Director of Molecular Partners AG since October 31, 2017. He was responsible for the achievement of full freedom to operate by licensing several key technologies and now oversees business development and strategic Partnering. During his work at Molecular Partners, he has established a whole range of fruitful commercial and academic collaborations. He holds a master of science from the ETH and earned his PhD at the University of Zurich.

CEO Compensation
  • Patrick's compensation has increased whilst company is loss making.
  • Patrick's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Molecular Partners management team in years:

2.8
Average Tenure
52
Average Age
  • The tenure for the Molecular Partners management team is about average.
Management Team

Patrick Amstutz

TITLE
Co-Founder
COMPENSATION
CHF909K
AGE
43
TENURE
2.4 yrs

Michael Stumpp

TITLE
Co-Founder
AGE
46
TENURE
15.3 yrs

Andreas Emmenegger

TITLE
CFO & Member of Management Board
AGE
52
TENURE
12 yrs

Andreas Harstrick

TITLE
Chief Medical Officer & Member of Management Board
AGE
57

Pam Trail

TITLE
Chief Scientific Officer & Member of Management Board
AGE
62
TENURE
0.8 yrs

Hans Binz

TITLE
Vice President of Technology

Thomas Schneckenburger

TITLE
Vice President of Finance

Julien Gander

TITLE
General Counsel
TENURE
2.8 yrs

Thomas Schwerzmann

TITLE
Vice President of Human Resources

Alexander Zürcher

TITLE
Senior Vice President of Development
Board of Directors Tenure

Average tenure and age of the Molecular Partners board of directors in years:

1.9
Average Tenure
64
Average Age
  • The average tenure for the Molecular Partners board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bill Burns

TITLE
Chairman of the Board
COMPENSATION
CHF305K
AGE
71
TENURE
1 yrs

Patrick Amstutz

TITLE
Co-Founder
COMPENSATION
CHF909K
AGE
43
TENURE
1.5 yrs

Göran Ando

TITLE
Vice-Chairman of the Board of Directors
COMPENSATION
CHF98K
AGE
69
TENURE
1.1 yrs

Petri Vainio

TITLE
Non Executive Director
COMPENSATION
CHF103K
AGE
59
TENURE
10.3 yrs

Bill Lee

TITLE
Non Executive Director
COMPENSATION
CHF106K
AGE
63
TENURE
12.3 yrs

Steve Holtzman

TITLE
Non Executive Director
COMPENSATION
CHF95K
AGE
64
TENURE
5.3 yrs

Gwen Fyfe

TITLE
Director
COMPENSATION
CHF96K
AGE
66
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Molecular Partners's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Molecular Partners has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6ML News

Simply Wall St News

6ML Company Info

Description

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema diseases, as well as on a partnered pipeline that includes novel approaches to the treatment of severe ocular diseases. The company also develops MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc.; Janssen Biotech, Inc.; and Amgen SA. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.

Details
Name: Molecular Partners AG
6ML
Exchange: DB
Founded: 2004
CHF342,131,802
21,257,002
Website: http://www.molecularpartners.com
Address: Molecular Partners AG
Wagistrasse 14,
Schlieren,
Zurich, 8952,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX MOLN Registered Shares SIX Swiss Exchange CH CHF 04. Nov 2014
OTCPK MLLC.F Registered Shares Pink Sheets LLC US USD 04. Nov 2014
DB 6ML Registered Shares Deutsche Boerse AG DE EUR 04. Nov 2014
LSE 0QXX Registered Shares London Stock Exchange GB CHF 04. Nov 2014
Number of employees
Current staff
Staff numbers
118
Molecular Partners employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:14
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.